2020
COVID-19 in Brazil: advantages of a socialized unified health system and preparation to contain cases
Croda J, de Oliveira W, Frutuoso R, Mandetta L, Baia-da-Silva D, Brito-Sousa J, Monteiro W, Lacerda M. COVID-19 in Brazil: advantages of a socialized unified health system and preparation to contain cases. Revista Da Sociedade Brasileira De Medicina Tropical 2020, 53: e20200167. PMID: 32320998, PMCID: PMC7182282, DOI: 10.1590/0037-8682-0167-2020.Peer-Reviewed Original ResearchConceptsCoronavirus disease 2019New coronavirus disease 2019Public health emergencyWorld Health OrganizationCOVID-19 casesUnified Health SystemDisease 2019First COVID-19 caseSevere casesHealth systemHealth OrganizationHealth emergencyCOVID-19First caseFuture studiesInternational concernEarly preparation
2018
The safe use of Doliocarpus dentatus in the gestational period: Absence of changes in maternal reproductive performance, embryo-fetal development and DNA integrity
Ishikawa R, Vani J, das Neves S, Rabacow A, Kassuya C, Croda J, Cardoso C, Monreal A, Antoniolli A, Cunha-Laura A, Oliveira R. The safe use of Doliocarpus dentatus in the gestational period: Absence of changes in maternal reproductive performance, embryo-fetal development and DNA integrity. Journal Of Ethnopharmacology 2018, 217: 1-6. PMID: 29408581, DOI: 10.1016/j.jep.2018.01.034.Peer-Reviewed Original ResearchConceptsFemale Swiss miceDoliocarpus dentatusSwiss miceEmbryofetal developmentGestational periodControl groupPregnant female Swiss miceEnd of pregnancyEmbryo-fetal developmentMaternal reproductive performanceReproductive performanceSafe useEmbryofoetal developmentUrinary retentionOral gavageAbsence of changesDNA integrityAntimycobacterial actionFetal developmentReproductive parametersFormation of micronucleiEthanolic extractPregnancySignificant differencesExperimental group
2009
Benefit of antiretroviral therapy on survival of human immunodeficiency virus-infected patients admitted to an intensive care unit
Croda J, Croda M, Neves A, dos Santos S. Benefit of antiretroviral therapy on survival of human immunodeficiency virus-infected patients admitted to an intensive care unit. Critical Care Medicine 2009, 37: 1605-1611. PMID: 19325488, PMCID: PMC4143892, DOI: 10.1097/ccm.0b013e31819da8c7.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Retroviral AgentsAntiretroviral Therapy, Highly ActiveBrazilCohort StudiesConfidence IntervalsCritical CareCritical IllnessDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesHIV InfectionsHospital MortalityHumansIntensive Care UnitsLogistic ModelsMaleMiddle AgedMultivariate AnalysisOdds RatioProportional Hazards ModelsRetrospective StudiesRisk AssessmentSurvival AnalysisConceptsIntensive care unitAntiretroviral therapyICU admissionCare unitChronic Health Evaluation II scoreHuman immunodeficiency virus-infected patientsCD4 T-cell countUse of ARTTertiary care teaching hospitalMultivariate logistic regression analysisCox proportional hazards modelAcute illness severityRetrospective cohort studyT-cell countsVirus-infected patientsDay of admissionHuman immunodeficiency virusCause of admissionProportional hazards modelPotential confounding factorsLogistic regression analysisAcute PhysiologyICU mortalityII scoreCohort study